Studies recently published in Arthritis & Rheumatism show that a key chemical produced by the central nervous system (CNS) decreases inflammation and suppresses production of proteins known to play a role in rheumatoid arthritis (RA). This opens the way for developing a novel class of drugs that mimic this effect of the CNS on RA.
Articles by Staff
Pharmaceutical Tourism
Could trade agreements and not bulky legislation be the key to cheaper drugs?
The Canes of York
What can a walking stick tell us about U.S. healthcare?
The Health Buzz
What is the ACR doing with healthcare reform?
A New Home for the ACR
The Atlanta headquarters are moving to a building purchased by the College
Neurological Piece of the Fibromyalgia Puzzle
Exploring the peripheral and central elements of pain in FM
Rheumatology Guy
Sung to the Tune of “American Pie”
Reading Rheum
Handpicked Reviews of Contemporary Literature
Insurer Updates
Policy Changes and IFA Codes
Pearls for Preauthorization: Part Two
Last month’s “Rheumatology Practice Pearls” focused on the denial or return of preauthorization requests because of missing data. This month’s pearls focuses on obtaining authorization for off-label drugs and updating a previous preauthorization.
- « Previous Page
- 1
- …
- 96
- 97
- 98
- 99
- 100
- …
- 149
- Next Page »